🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

Recruitingn/aAges 18 Years - anyAllPfizer
NCT05689151 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis. Atopic dermatitis, or AD, is a long-lasting disease that causes inflammation, redness, and irritation of the skin. This study is seeking participant who are older than 18 years with moderate-to-severe chronic AD. Participants must have no underlying medical conditions that prevent them from taking Abrocitinib. All participants in this study will receive Abrocitinib as a tablet once daily. They can take Abrocitinib and use medicated topical treatment for AD at the same time. We will examine the experiences of patients receiving the study medicine. This will help us determine if the study medicine is safe and helps in treating AD. Participants will take part in this study for 24 months. During this time, the

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients older than 18 years of age at inclusion. * Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval. * Patients that have been informed of the study procedures and have signed the consent. Exclusion Criteria: * Patients for whom abrocitinib is contraindicated. * Patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons. * Patients not affiliated to the French social security system. * Patients deprived of liberty, under guardianship, or unable to provide oral consent. * Patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).
💊

What it tests

  • Abrocitinib
📍

Where

30 sites
CHU Amiens-Picardie - Site Nord
Amiens, France
CHU Besancon - Hopital Jean Minjoz
Besançon, France
Polyclinique Reims Bezannes
Bezannes, France
Chu Bordeaux Hopital Saint Andre
Bordeaux, France
CHU Brest Hopital Morvan
Brest, France
CHU de Caen
Caen, France
Ch de Calais
Calais, France
Ch William Morey
Chalon-sur-Saône, France

…and 22 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy